Article

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Rm 4512, Bethesda, MD 20892, USA.
Journal of Virology (Impact Factor: 4.65). 03/2006; 80(3):1414-26. DOI: 10.1128/JVI.80.3.1414-1426.2006
Source: PubMed

ABSTRACT We previously reported that soluble, stable YU2 gp140 trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein immunogens could elicit improved breadth of neutralization against HIV-1 isolates compared to monomeric YU2 gp120 proteins. In this guinea pig immunization study, we sought to extend these data and determine if adjuvant could quantitatively or qualitatively alter the neutralizing response elicited by trimeric or monomeric immunogens. Consistent with our earlier studies, the YU2 gp140 immunogens elicited higher-titer neutralizing antibodies against homologous and heterologous isolates than those elicited by monomeric YU2 gp120. Additionally, the GlaxoSmithKline family of adjuvants AS01B, AS02A, and AS03 induced higher levels of neutralizing antibodies compared to emulsification of the same immunogens in Ribi adjuvant. Further analysis of vaccine sera indicated that homologous virus neutralization was not mediated by antibodies to the V3 loop, although V3 loop-directed neutralization could be detected for some heterologous isolates. In most gp120-inoculated animals, the homologous YU2 neutralization activity was inhibited by a peptide derived from the YU2 V1 loop, whereas the neutralizing activity elicited by YU2 gp140 trimers was much less sensitive to V1 peptide inhibition. Consistent with a less V1-focused antibody response, sera from the gp140-immunized animals more efficiently neutralized heterologous HIV-1 isolates, as determined by two distinct neutralization formats. Thus, there appear to be qualitative differences in the neutralizing antibody response elicited by YU2 gp140 compared to YU2 monomeric gp120. Further mapping analysis of more conserved regions of gp120/gp41 may be required to determine the neutralizing specificity elicited by the trimeric immunogens.

Download full-text

Full-text

Available from: Richard Wyatt, Jul 26, 2015
0 Followers
 · 
63 Views
  • Source
    • "As for viral particle-based vaccines, immunization with these constructs has resulted in the elicitation of predominantly nonneutralizing or strain-specific antibody responses (see above). Immunogens Based on the Epitopes Recognized by bnAbs A significant fraction of HIV-infected individuals develop broadly neutralizing responses over time (Binley et al., 2008; Doria-Rose et al., 2009; Gray et al., 2009, 2011; Li et al., 2006; Sather et al., 2009; Simek et al., 2009; Stamatatos et al., 2009), including some ''elite neutralizers,'' who display outstanding serum neutralization potency (Simek et al., 2009). Mapping of serum responses in broad neutralizers shows the targeting of a relatively small number of broadly neutralizing epitopes on Env, such as the CD4 binding site (CD4bs), glycan-dependent epitopes, quaternary structure dependent epitopes, and the membrane proximal external region (MPER) (Gray et al., 2009; Stamatatos et al., 2009; Walker et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite numerous attempts over many years to develop an HIV vaccine based on classical strategies, none has convincingly succeeded to date. A number of approaches are being pursued in the field, including building upon possible efficacy indicated by the recent RV144 clinical trial, which combined two HIV vaccines. Here, we argue for an approach based, in part, on understanding the HIV envelope spike and its interaction with broadly neutralizing antibodies (bnAbs) at the molecular level and using this understanding to design immunogens as possible vaccines. BnAbs can protect against virus challenge in animal models, and many such antibodies have been isolated recently. We further propose that studies focused on how best to provide T cell help to B cells that produce bnAbs are crucial for optimal immunization strategies. The synthesis of rational immunogen design and immunization strategies, together with iterative improvements, offers great promise for advancing toward an HIV vaccine.
    Cell host & microbe 10/2012; 12(4):396-407. DOI:10.1016/j.chom.2012.09.008 · 12.19 Impact Factor
  • Source
    • "It is also clear that such pre-defined recognition cannot be achieved with conventional vaccine formulations. Therefore, novel structurebased immunogen design strategies are being explored, some in conjunction with modern adjuvant formulation technologies [252], to selectively stimulate B cell responses that exhibit the desired neutralizing activity and breadth to counter the sequence diversity of HIV [143] [253]. A better understanding of how to stimulate maturation of the desired B cells, for example by studying B cell receptor usage at the genetic and phenotype levels and in-depth analyses of subset composition in the B-cell compartment, could further assist rational design efforts. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Formulating an effective HIV vaccine remains a formidable challenge despite nearly 3 decades of intense research since the virus was first isolated. One of the obstacles that need to be surmounted is the design of a preparation that elicits a potent and broadly neutralizing antibody (nAb) response, i.e. antibodies with the capacity to block infectivity of the genetically diverse pool of HIV strains that circulate globally. The primary target for nAbs on HIV-1 is the envelope glycoprotein spike (Env). Early work on elucidating the exposure of antibody epitopes on Env suggested highly restricted accessibility of antibodies to epitopes that are conserved among otherwise diverse virus isolates. Crystal structures of Env-derived antigens, most in complex with antibodies, along with structure-function studies and molecular modeling, have provided significant further insight into features of Env that limit broad antibody recognition. Despite these challenges, recent progress on various fronts has led to a growing sense that Env is not as impenetrable to nAbs as might have been believed in the past. Increased understanding of antibody epitope exposure on Env should provide new impulses for efforts to elicit nAbs that can protect against HIV-1 infection.
    Current pharmaceutical design 11/2010; 16(33):3729-43. DOI:10.2174/138161210794079182 · 3.29 Impact Factor
  • Source
    • "Theses studies suggest that some mAb target quaternary structures present only on the surfaces of intact virions. Data presented here, our work (Liao et al., 2006) and other's work (Beddows et al., 2007; Chakrabarti et al., 2002; Crooks et al., 2007; Kwong et al., 1998; Li et al., 2006b; Lin and Nara, 2007; Srivastava et al., 2003; Tobin et al., 2008; Wyatt et al., 1998) in animals, as well as immunizations in man (Gilbert et al., 2005; Lee et al., 2001) all demonstrate that recombinant Envs though antigenic and binding broadly neutralizing antibodies are, as yet, do not induce sufficiently broad-reactive neutralizing antibodies in standard TZMbL cell neutralization assays. Moreover, that these specificities of antibodies induced in mice do not capture virions demonstrates they will not block virions traversing mucosal surfaces. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The extraordinarily high level of genetic variation of HIV-1 env genes poses a challenge to obtain antibodies that cross-react with multiple subtype Env glycoproteins. To determine if cross-reactive monoclonal antibodies (mAbs) to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced, we immunized mice with wild-type or consensus HIV-1 Env proteins and characterized a panel of ten mAbs that reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env proteins by ELISA and Western blot analysis. Two mAbs (3B3 and 16H3) cross-reacted with all tested Env proteins, including SIVcpzUS Env. Surface plasmon resonance analyses showed both 3B3 and 16H3 bound Env proteins with high affinity. However, neither neutralized primary HIV-1 pseudoviruses. These data indicate that broadly reactive non-neutralizing monoclonal antibodies can be elicited, but that the conserved epitopes that they recognize are not present on functional virion trimers. Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers.
    Virology 10/2009; 394(1):91-8. DOI:10.1016/j.virol.2009.07.041 · 3.28 Impact Factor
Show more